Holen Sie sich die Stockscreener-App
51.60
1.86%
0.94
Schlusskurs vom Vortag:
$50.66
Offen:
$51.14
24-Stunden-Volumen:
5.49M
Relative Volume:
1.20
Marktkapitalisierung:
$104.08B
Einnahmen:
$42.06B
Nettoeinkommen (Verlust:
$7.96B
KGV:
14.72
EPS:
3.5061
Netto-Cashflow:
$5.65B
1W Leistung:
+4.98%
1M Leistung:
+4.67%
6M Leistung:
+32.41%
1J Leistung:
+45.93%
1-Tages-Spanne:
$51.05
$51.69
1-Wochen-Bereich:
$49.59
$51.69
52-Wochen-Spanne:
$32.38
$51.69
Gsk Plc Adr Stock (GSK) Company Profile
Vergleichen Sie GSK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
51.60 | 102.18B | 42.06B | 7.96B | 5.65B | 3.5061 |
|
LLY
Lilly Eli Co
|
1,037.15 | 916.62B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
227.25 | 547.61B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.01 | 389.58B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
148.68 | 285.73B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
110.27 | 268.90B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2026-01-06 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-11-25 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-03 | Herabstufung | Berenberg | Buy → Hold |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-07-08 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-03-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2024-01-03 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-03-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Fortgesetzt | Goldman | Buy |
| 2023-01-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Herabstufung | UBS | Neutral → Sell |
| 2022-09-15 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Fortgesetzt | Citigroup | Neutral |
| 2022-02-11 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Hold |
| 2020-11-02 | Hochstufung | Liberum | Hold → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-02-12 | Herabstufung | Shore Capital | Hold → Sell |
| 2020-01-16 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-21 | Hochstufung | UBS | Neutral → Buy |
| 2019-10-11 | Hochstufung | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Fortgesetzt | Citigroup | Neutral |
| 2019-09-03 | Hochstufung | Societe Generale | Sell → Buy |
| 2019-08-13 | Fortgesetzt | JP Morgan | Neutral |
| 2019-06-17 | Fortgesetzt | Morgan Stanley | Underweight |
| 2019-03-08 | Herabstufung | Shore Capital | Buy → Hold |
| 2019-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-14 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-08-30 | Herabstufung | Liberum | Buy → Hold |
| 2018-04-04 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Hochstufung | Kepler | Reduce → Hold |
Alle ansehen
Gsk Plc Adr Aktie (GSK) Neueste Nachrichten
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle - Benzinga
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Oncolytic Virotherapy Market - GlobeNewswire Inc.
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout - Finviz
GSK plc (ADR): Defensive pharma heavyweight tests investors’ patience as Wall Street edges cautiou - AD HOC NEWS
Price Over Earnings Overview: GSK - Sahm
GSK To Acquire RAPT Therapeutics In $2.2 Billion Bet On Food Allergy Breakthrough - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Sees Significant Growth in Short Interest - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Recommendation of "Reduce" from Brokerages - MarketBeat
GSK plc (ADR): Defensive Pharma Giant Tests Investors’ Patience As Shares Slip Despite Solid Pipel - AD HOC NEWS
Looking Into GSK PLC's Recent Short Interest - Sahm
Jefferies Reaffirms a Buy Rating on GSK plc (GSK)Here's Why - Finviz
GSK's chronic hepatitis B drug meets goals in two late-stage studies - MSN
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies - TradingView — Track All Markets
GSK (NYSE:GSK) Lowered to “Underweight” Rating by Barclays - Defense World
US Cuts Childhood Vaccine Schedule To 11 Core Shots— What It Means For Vaccine Makers Like Merck And GSK - Sahm
Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz
The Truth About GSK plc (ADR): Viral Hype Or Sneaky Safe Bet For Your Portfolio? - AD HOC NEWS
GSK plc (ADR): Defensive Giant Or Underestimated Comeback Story? - AD HOC NEWS
The Truth About GSK plc (ADR): Is Wall Street Sleeping on This Pharma Beast? - AD HOC NEWS
GSK plc (ADR): Defensive Pharma Heavyweight Tests Investor Patience As Street Turns Selectively Bull - AD HOC NEWS
The Truth About GSK plc (ADR): Is This ‘Boring’ Stock Quietly Becoming a Power Play? - AD HOC NEWS
Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm
The Truth About GSK plc (ADR): Is Wall Street Sleeping On This Pharma Beast? - AD HOC NEWS
New Report Calls Achieve Life's Cytisinicline Best Therapy To Quit Smoking - Sahm
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally - ts2.tech
The Market Is All In on the Magnificent Seven. Where Should Investors Look Next? - Morningstar
HSBC Sees Pharma Poised to Outperform in 2026, Lifts GSK Target - Finviz
Why is GSK plc (GSK) One of the Best Affordable Healthcare Stocks to Buy Now? - Finviz
Bard Financial Services Inc. Purchases 23,400 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK plc Sponsored ADR (GSK) Stock Price History & Data - Traders Union
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of “Hold” by Brokerages - Defense World
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages - MarketBeat
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK - Sahm
Douglas Lane & Associates LLC Sells 196,210 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst - Sahm
GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc - ts2.tech
Finanzdaten der Gsk Plc Adr-Aktie (GSK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):